Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure
暂无分享,去创建一个
A. Bender | J. Jenkins | J. Scheiber | M. Glick | J. Davies | K. Azzaoui | S. Whitebread | J. Hamon | L. Urban
[1] [COMPLEX CARDIAC ARRYTHMIAS IN THE COURSE OF ACUTE INTOXICATION DUE TO FUNGICIDE ACETYLCHOLINESTERASE INHIBITORS]. , 1964, Minerva medica.
[2] P. Williams. The role of pharmacological profiling in safety assessment. , 1990, Regulatory toxicology and pharmacology : RTP.
[3] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[4] E. Green,et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.
[5] K. Broadley,et al. Muscarinic Receptor Agonists and Antagonists , 2001, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.
[6] F. Charatan. Exercise and diet reduce risk of diabetes, US study shows , 2001, BMJ : British Medical Journal.
[7] Wolfgang Guba,et al. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.
[8] Sean Ekins,et al. Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs , 2002 .
[9] S. Wolfe,et al. Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.
[10] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[11] D. Snodin. An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology. , 2002, Toxicology letters.
[12] Adrian H Elcock,et al. Progress toward virtual screening for drug side effects , 2002, Proteins.
[13] Gisbert Schneider,et al. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.
[14] R. Leurs,et al. H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[15] K. Olejniczak,et al. ICH Topic: The draft ICH S7B step 2: Note for guidance on safety pharmacology studies for human pharmaceuticals , 2002, Fundamental & clinical pharmacology.
[16] Sean Ekins,et al. A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[17] J. Valentin,et al. The application of in vitro methods to safety pharmacology , 2002, Fundamental & clinical pharmacology.
[18] Hugo A Katus,et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels , 2003, British journal of pharmacology.
[19] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[20] Roy J. Vaz,et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.
[21] John D. Walker,et al. Quantitative structure–activity relationships (QSARs) in toxicology: a historical perspective , 2003 .
[22] B. Shoichet,et al. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. , 2003, Journal of medicinal chemistry.
[23] Pierre Acklin,et al. Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..
[24] Peter Jüni,et al. Lessons from the withdrawal of rofecoxib , 2004, BMJ : British Medical Journal.
[25] S. Ekins. Predicting undesirable drug interactions with promiscuous proteins in silico. , 2004, Drug discovery today.
[26] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[27] J. Stachura,et al. Inhibition of cyclooxygenase-2 reduces the protective effect of hepatocyte growth factor in experimental pancreatitis. , 2004, European journal of pharmacology.
[28] Patricia Williams,et al. Origins, practices and future of safety pharmacology. , 2004, Journal of pharmacological and toxicological methods.
[29] Andreas Bender,et al. Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..
[30] R. Botting,et al. Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.
[31] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[32] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[33] D. Bojanic,et al. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.
[34] J. Meyer,et al. Die mechanoelektrische Transduktion der äußeren Haarzelle wird durch Azetylsalizylsäure in vitro nicht beeinflusst , 2006, HNO.
[35] A. Fliri,et al. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.
[36] A. Fliri,et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.
[37] T. Klabunde,et al. GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.
[38] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[39] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[40] P. Hoffmann,et al. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. , 2006, Journal of pharmacological and toxicological methods.
[41] A. Bender,et al. In silico target fishing: Predicting biological targets from chemical structure , 2006 .
[42] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[43] U. Moretti,et al. Upper gastrointestinal bleeding associated with antiplatelet drugs , 2006, Alimentary pharmacology & therapeutics.
[44] Esther F. Schmid,et al. Drug withdrawals and the lessons within. , 2006, Current opinion in drug discovery & development.
[45] Z. Deng,et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.
[46] A. Furlan,et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects , 2006, Canadian Medical Association Journal.
[47] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..
[48] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.